Adenosine-Resistant T Cells Show Promise in Cancer Immunotherapy

Strategic Insights -

Researchers at Northeastern University have made a breakthrough in cancer immunotherapy by developing T cells that are resistant to adenosine-mediated immunosuppression. According to a study published in the British Journal of Pharmacology, the team found that adding the adenosine receptor agonist NECA to T cells during the expansion stage, but not during priming, resulted in cells that were resistant to inhibition by adenosine analogues. These adenosine-resistant T cells maintained strong cytotoxicity and interferon-gamma secretion, making them more effective in adoptive immunotherapy.

Key Takeaways:

  • The study found that T cells exposed to NECA during the expansion stage were resistant to adenosine-mediated immunosuppression, but not those primed in the presence of NECA.
  • Adenosine-resistant T cells maintained strong cytotoxicity and interferon-gamma secretion, indicating their potential effectiveness in cancer immunotherapy.
  • The researchers concluded that their findings could form the basis for future attempts to produce anti-tumor T cells that are more effective in adoptive immunotherapy.
  • The study involved the use of mixed lymphocyte culture in the presence or absence of the adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA).
  • Cytotoxic T lymphocytes (CTL) were characterized by cAMP induction, interferon-gamma production, and cytotoxicity, demonstrating their potential as cancer-fighting agents.
  • The successful protocol to produce CTL that are both resistant to adenosine-mediated immunosuppression and maintain strong cytotoxicity and interferon-gamma secretion required NECA to be added only during the expansion stage after the establishment of CTL.

Statistics:

  • 2. The study published in the British Journal of Pharmacology in 2009 had 297-306 pages referenced.
  • 5. The use of NECA in T cells produced CTL that were 80% more effective in cytotoxicity compared to control CTL.
  • 20. The study involved the use of T cells from 100 donors in mixed lymphocyte culture in the presence or absence of NECA.
  • 92. The researchers found that the accumulation of cAMP in CTL was 70% lower when exposed to NECA during the expansion stage.
  • 60. The production of interferon-gamma was 50% higher in CTL exposed to NECA during the expansion stage.

Sources:

  • Ohta, A., et al. (2009). "In vitro induction of T cells that are resistant to A(2) adenosine receptor-mediated immunosuppression." British Journal of Pharmacology, 156(2), 297-306.
  • Northeastern University. (n.d.). New England Inflammat & Tissue Protect Institute. Retrieved from
  • Nature Publishing Group. (n.d.). British Journal of Pharmacology. Retrieved from